Citations Report

Articles published in Clinical Schizophrenia & Related Psychoses have been cited by esteemed scholars and scientists all around the world. Clinical Schizophrenia & Related Psychoses has got h-index 41, which means every article in Clinical Schizophrenia & Related Psychoses has got 41 average citations.

Following are the list of articles that have cited the articles published in Clinical Schizophrenia & Related Psychoses.

Hoertel, Nicolas, Léa Rotenberg, Carlos Blanco, Vincent Camus, Caroline Dubertret, Véronique Charlot, Franck Schürhoff, Pierre Vandel, and Frédéric Limosin. "A comprehensive model of predictors of quality of life in older adults with schizophrenia: results from the CSA study." Social psychiatry and psychiatric epidemiology 56, no. 8 (2021): 1411-1425.

Knott, Verner, Dhrasti Shah, Anne Millar, Judy McIntosh, Derek Fisher, Crystal Villeneuve, and Vadim Ilivitsky. "Nicotine, auditory sensory memory, and sustained attention in a human ketamine model of schizophrenia: moderating influence of a hallucinatory trait." Frontiers in pharmacology 3 (2012): 172.

Martínez-Cengotitabengoa, Mónica, Juan Antonio Micó, Celso Arango, Josefina Castro-Fornieles, Montserrat Graell, Beatriz Payá, Juan Carlos Leza et al. "Basal low antioxidant capacity correlates with cognitive deficits in early onset psychosis. A 2-year follow-up study." Schizophrenia research 156, no. 1 (2014): 23-29.

Ayyildiz, Hakan, Nuran Karabulut, and Mehmet Kalayci. "Research Article Relationship between red blood cell distribution width and schizophrenia." Int J Med Biochem 1, no. 1 (2018): 15-9.

Correll, Christoph U., Daisy S. Ng-Mak, Dana Stafkey-Mailey, Eileen Farrelly, Krithika Rajagopalan, and Antony Loebel. "Cardiometabolic comorbidities, readmission, and costs in schizophrenia and bipolar disorder: a real-world analysis." Annals of general psychiatry 16, no. 1 (2017): 1-8.

Grannan, Michael D., Catharine A. Mielnik, Sean P. Moran, Robert W. Gould, Jacob Ball, Zhuoyan Lu, Michael Bubser et al. "Prefrontal cortex-mediated impairments in a genetic model of NMDA receptor hypofunction are reversed by the novel M1 PAM VU6004256." ACS chemical neuroscience 7, no. 12 (2016): 1706-1716.

Young, Su Ling, Mark Taylor, and Stephen M. Lawrie. "“First do no harm.” A systematic review of the prevalence and management of antipsychotic adverse effects." Journal of psychopharmacology 29, no. 4 (2015): 353-362.

Martins-de-Souza, Daniel, Paul C. Guest, Hassan Rahmoune, and Sabine Bahn. "Proteomic approaches to unravel the complexity of schizophrenia." Expert review of proteomics 9, no. 1 (2012): 97-108.

Laursen, Thomas Munk, Merete Nordentoft, and Preben Bo Mortensen. "Excess early mortality in schizophrenia." Annual review of clinical psychology 10 (2014): 425-448.

Copeland, C. S., S. A. Neale, and T. E. Salt. "Actions of Xanthurenic Acid, a putative endogenous Group II metabotropic glutamate receptor agonist, on sensory transmission in the thalamus." Neuropharmacology 66 (2013): 133-142.

Perry, Benjamin I., Stanley Zammit, Peter B. Jones, and Golam M. Khandaker. "Childhood inflammatory markers and risks for psychosis and depression at age 24: examination of temporality and specificity of association in a population-based prospective birth cohort." Schizophrenia Research 230 (2021): 69-76.

Bugarski-Kirola, Dragana, Nakao Iwata, Snjezana Sameljak, Carol Reid, Thomas Blaettler, Laurie Millar, Tiago Reis Marques, George Garibaldi, and Shitij Kapur. "Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme." The Lancet Psychiatry 3, no. 12 (2016): 1115-1128.

Crespi, B. J., and D. L. Thiselton. "Comparative immunogenetics of autism and schizophrenia." Genes, Brain and Behavior 10, no. 7 (2011): 689-701.

Alabsi, Wafaa, Fahad A. Al-Obeidi, Robin Polt, and Heidi M. Mansour. "Organic Solution Advanced Spray-Dried Microparticulate/Nanoparticulate Dry Powders of Lactomorphin for Respiratory Delivery: Physicochemical Characterization, In Vitro Aerosol Dispersion, and Cellular Studies." Pharmaceutics 13, no. 1 (2021): 26.

Reponen, Elina J., Ingrid Dieset, Martin Tesli, Ragni H. Mørch, Monica Aas, Trude SJ Vedal, Elisabeth Haug et al. "Atherogenic lipid ratios related to myeloperoxidase and c-reactive protein levels in psychotic disorders." Frontiers in Psychiatry 11 (2020).

Spyker, Daniel A., James V. Cassella, Randall R. Stoltz, and Paul P. Yeung. "Inhaled loxapine and intramuscular lorazepam in healthy volunteers: a randomized placebo?controlled drug–drug interaction study." Pharmacology research & perspectives 3, no. 6 (2015): e00194.

Seeman, Mary V. "The gut microbiome and treatment-resistance in schizophrenia." Psychiatric Quarterly 91, no. 1 (2020): 127-136.

Iasevoli, Felice, Raffaele Balletta, Valentina Gilardi, Sara Giordano, and Andrea De Bartolomeis. "Tobacco smoking in treatment-resistant schizophrenia patients is associated with impaired cognitive functioning, more severe negative symptoms, and poorer social adjustment." Neuropsychiatric Disease and Treatment 9 (2013): 1113.

Faden, Justin, and Leslie Citrome. "Examining the safety, efficacy, and patient acceptability of inhaled loxapine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults." Neuropsychiatric disease and treatment 15 (2019): 2273.

Osimo, Emanuele F., Benjamin I. Perry, Rudolf N. Cardinal, Mary-Ellen Lynall, Jonathan Lewis, Arti Kudchadkar, Graham K. Murray, Jesus Perez, Peter B. Jones, and Golam M. Khandaker. "Inflammatory and cardiometabolic markers at presentation with first episode psychosis and long-term clinical outcomes: a longitudinal study using electronic health records." Brain, behavior, and immunity 91 (2021): 117-127.